Clinical trials: Immune Related Disorder
HIV Infections, Condyloma Acuminata
The Safety and Effectiveness of Cidofovir in the Treatment of Venereal Warts in HIV-Infected Patients
To evaluate the safety and tolerance of topical cidofovir (HPMPC) therapy for condyloma acuminatum in patients with HIV infection.
- Trial name
- NCT00002327
- Testing
- Cidofovir
- Where
- 11 sites in United States
- Volunteers
- 40 people
- Sponsor
- Gilead Sciences
HIV Infections
A Study of ddC in Patients With AIDS or Advanced AIDS-Related Complex (ARC) Who Have Not Had Success With Zidovudine (AZT)
AMENDED: To provide ddC for patients with AIDS or advanced ARC who have failed treatment with, are intolerant to or are ineligible to receive zidovudine (AZT) and to demonstrate that ddC monotherapy is safe, and tolerable in this…
- Trial name
- NCT00002279
- Testing
- Zalcitabine
- Where
- United States
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug
The purpose of the study is to test how well patients with advanced solid tumors respond to treatment with elimusertib (BAY1895344) in combination with pembrolizumab.
- Trial name
- NCT04095273
- Testing
- Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
- Where
- 16 sites in United States, Germany and 3 more
- Volunteers
- 56 people
- Sponsor
- Bayer
Allergic Rhinitis
Comparison of Desloratadine Associated With Prednisolone Oral Solution Versus Dexchlorpheniramine Associated With Betamethasone for Persistent Allergic Rhinitis Treatment
The purpose of this study is to evaluate the non-inferiority clinical efficacy of two different drug associations in the treatment of Moderate - Severe Persistent Allergic Rhinitis.
- Trial name
- NCT01529229
- Testing
- Dexchlorpheniramine + Betamethasone, Desloratadine + Prednisolone
- Volunteers
- 210 people
- Sponsor
- EMS
HIV Infections
A Phase I Study of Recombinant CD4(rCD4) in Patients With AIDS and AIDS-Related Complex
To determine the safety profile and maximum tolerated dose (MTD) of recombinant soluble human CD4 (rCD4) therapy in patients with AIDS or AIDS related complex (ARC).
- Trial name
- NCT00002005
- Testing
- CD4 Antigens
- Where
- United States
- Sponsor
- Genentech, Inc.
Asthma
Observational Study on Therapy Pathways of Asthamics Treated With ICS/LABA/LAMA Therapy in a Real-world Setting
TriMaximize is a non-interventional study aimed to collect prospective data from asthmatic patients under routine care, for whom their treating physician has decided to prescribe BDP/FF/G…
- Trial name
- TRIMAXIMIZE (NCT06100042)
- Testing
- BDP/FF/G
- Where
- Italy
- Volunteers
- 233 people
- Sponsor
- Chiesi Italia
Immunoglobulin G4 Related Disease
A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
This is a Phase 3, parallel group, 2-arm, randomized, double blind, placebo-controlled, 52-week treatment study to assess the efficacy and safety of rilzabrutinib as a treatment for adult patients with active IgG4-RD.
- Trial name
- RILIEF (NCT07190196)
- Testing
- Rilzabrutinib, Glucocorticoid
- Where
- 95 sites in United States, Argentina and 17 more
- Volunteers
- 124 people
- Sponsor
- Sanofi
Cytomegalovirus Retinitis, HIV Infections
A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
To determine the clinically safe and effective dose of intravitreal ISIS 2922 alone and as an additive antiviral therapy to ganciclovir in AIDS patients with cytomegalovirus (CMV) retinitis.
- Trial name
- NCT00002156
- Testing
- Fomivirsen sodium, Ganciclovir
- Where
- 18 sites in United States
- Volunteers
- 194 people
- Sponsor
- Ionis Pharmaceuticals, Inc.
HIV Infections
A Multi-Center, Open-Label, Ascending, Multiple Oral Dose, Safety, Tolerance and Pharmacokinetic Study of 3'-Deoxy-3'-Fluorothymidine (FLT) in Patients With Acquired Immune Deficiency Syndrome (AIDS) or AIDS-Related Complex (ARC)
To assess the tolerance and toxicity profile of deoxy-3'-fluorothymidine (FLT) after multiple oral dosing for 16 weeks. To characterize the steady-state pharmacokinetics of FLT after multiple oral doses.
- Trial name
- NCT00002254
- Testing
- Alovudine
- Where
- 3 sites in United States
- Sponsor
- Lederle Laboratories
Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe
A Brief Negotiation Interview Chatbot to Improve Buprenorphine Engagement Among Justice-Involved Individuals
Primary Objective: Conduct pilot study to assess effects of brief negotiation interview (BNI) Chatbot among individuals involved in the Connecticut criminal justice system with opioid use disorder (OUD).
- Conditions
- Opioid Use Disorder, Moderate, Opioid Use Disorder, Severe, Criminal Behavior
- Trial name
- BNICHAT (NCT04982627)
- Testing
- BNI Chatbot, OUD Education & Treatment Resources
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- Center for Progressive Recovery, LLC
Drug/Agent Toxicity by Tissue/Organ, Lymphoma
Dexamethasone Followed by Denileukin Diftitox in Treating Patients With Persistent or Recurrent T-Cell Lymphoma
RATIONALE: Denileukin diftitox may be able to deliver cancer-killing substances directly to T-cell lymphoma cells. Dexamethasone may decrease the side effects of denileukin diftitox.
- Trial name
- NCT00006345
- Testing
- denileukin diftitox, dexamethasone
- Where
- 11 sites in United States
- Sponsor
- Ligand Pharmaceuticals
Aspirin Exacerbated Respiratory Disease (AERD)
Trial to Determine the Safety of Oral Ifetroban in Patients With a History of Aspirin Exacerbated Respiratory Disease
The primary objective of the study is to determine the safety of oral ifetroban compared to placebo as measured by a > 20% decrease in FEV1 compared to baseline following a dose of Investigational Medicinal Product (IMP) (Study…
- Trial name
- NCT02216357
- Testing
- Ifetroban, Oral Capsule
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Cumberland Pharmaceuticals
Candidiasis, Oral, HIV Infections
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
To compare the efficacy, safety, and toleration of fluconazole as a single daily oral suspension for 14 days versus nystatin oral suspension 4 times daily for 14 days in the treatment of oropharyngeal candidiasis in patients with…
- Trial name
- NCT00002112
- Testing
- Nystatin, Fluconazole
- Where
- 5 sites in United States
- Sponsor
- Pfizer
Asthma
TriMaximize: A Multicentre, Prospective, Non-interventional Trial in Asthma Patients
TriMaximize: A multicentre, prospective, non-interventional trial monitoring therapy pathways of asthma patients treated with an extra-fine ICS/LABA/LAMA single-inhaler triple therapy in a real-world setting and characterizing…
- Trial name
- Trimaximize PL (NCT06567977)
- Testing
- Trimbow
- Where
- Poland
- Volunteers
- 60 people
- Sponsor
- Chiesi Poland Sp. z o.o.
Meningitis, Cryptococcal, HIV Infections
Multicenter Comparison of Fluconazole (UK-49,858) and Amphotericin B as Treatment for Acute Cryptococcal Meningitis
To compare the safety and effectiveness of fluconazole and amphotericin B, alone or in combination with flucytosine, as treatment for acute cryptococcal meningitis.
- Trial name
- NCT00002075
- Testing
- Flucytosine, Fluconazole, Amphotericin B
- Where
- United States
- Sponsor
- Pfizer
Leukoplakia, Hairy, HIV Infections
Treatment and Suppression of Hairy Leukoplakia in ARC Patients With Oral Acyclovir (ACV)
To evaluate the efficacy of oral acyclovir for the treatment and suppression of Epstein-Barr virus (EBV) related hairy leukoplakia (HL).
- Trial name
- NCT00002026
- Testing
- Acyclovir
- Where
- United States
- Sponsor
- Glaxo Wellcome
Pneumonia, Pneumocystis Carinii, HIV Infections
Dapsone 100 Mg Versus 50 as Primary Prophylaxis for Pneumocystis Carinii Pneumonia (PCP) in Patients With AIDS-Related Complex (ARC)
To determine which of 2 doses of dapsone is effective prophylaxis for Pneumocystis carinii pneumonia (PCP) in patients with oral thrush or hairy leukoplakia and less than 400 CD4 lymphocytes per mm3.
- Trial name
- NCT00002043
- Testing
- Dapsone
- Where
- United States
- Sponsor
- Jacobus Pharmaceutical
Candidiasis, Esophageal, HIV Infections
A Comparison of Fluconazole and Ketoconazole in the Treatment of Fungal Infections of the Throat in Patients With Weakened Immune Systems
To compare the safety, tolerance, and effectiveness of fluconazole and ketoconazole in the treatment of candidal esophagitis in immunocompromised patients.
- Trial name
- NCT00002304
- Testing
- Ketoconazole, Fluconazole
- Where
- 42 sites in United States, Canada
- Sponsor
- Pfizer
Candidiasis, Oral, HIV Infections
A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes
To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)
- Trial name
- NCT00002293
- Testing
- Nystatin
- Where
- 2 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Double-Blind Comparison of the Efficacy of Continued Zidovudine Versus 2',3'-Dideoxyinosine (ddI) (BMY-40900) for the Treatment of Patients With AIDS or AIDS-Related Complex and Increasing Symptomatology Despite Treatment With Zidovudine
To compare the efficacy and safety of orally administered didanosine (ddI) with orally administered zidovudine (AZT) in the treatment of patients who exhibit increasing clinical deterioration despite treatment with AZT.
- Trial name
- NCT00002035
- Testing
- Zidovudine, Didanosine
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb